Biotech Values

[DewDiligence]

CHMP approves Tradjenta (linagliptin), a DPP-4 inhibitor from B-I/LLY:

http://finance.yahoo.com/news/Linagliptin-recommended-for-prnews-3129747740.html?x=0&.v=2

Tradjenta was approved by the FDA one month ago (#msg-62668535).

Despite the fact that the DPP-4 arena is crowded, LLY paid B-I a large amount of money in Jan 2011 to collaborate on Tradjenta and other diabetes drugs (#msg-58667443). This is the collaboration that caused AMLN to sue LLY for breach of the Byetta/Bydureon partnership terms.